



SOFIE
From start to clinic

December 08, 2017

Jan Nguyen
NRC Region I
475 Allendale Road
King of Prussia, PA 19406

Bryan Parker
NRC Region III
2443 Warrenville Rd, Suite 210
Leslie, IL 60532-4352

SUBJECT: Notice of Corporate Name Change for NRC Radioactive Material Licenses No. 45-25221-05 and 45-25221-01MD

Dear Sir or Ma'am,

Effective December 17, 2017, Zevacor Pharma, Inc. ("Zevacor") will change its corporate name and begin operating as SOFIE Co. dba SOFIE. This name change is the conclusion of the corporate acquisition of which Zevacor previously notified the Nuclear Regulatory Commission.

The federal tax ID and DUNs number associated with Zevacor, now SOFIE Co., will not change as a result of this name change. No changes to the corporate organization, licensed activities, or personnel responsible for licensed activities are impacted by the corporate name change. The corporate offices will be maintained at 21000 Atlantic Boulevard, Suite 730, Dulles, Virginia 20166.

Therefore, Zevacor requests that the Nuclear Regulatory Commission amend its records and NRC Radioactive Material License 45-25221-05 and 45-25221-01MD to reflect SOFIE Co. as the licensee.

Additionally, please direct all regulatory correspondence to SOFIE Co. Regulatory Affairs:

Frank Plastini, Director of Radiation Compliance
SOFIE Co. dba SOFIE
21000 Atlantic Blvd., Suite 730
Dulles, VA 20166

Please contact me at (518) 313-2369 or at frank.plastini@sofie.com if further information is required.

Sincerely,

Frank Plastini
Director of Radiation Compliance
SOFIE Co.